Efmoroctocog alfa

N/A

Report date: 2022/06/20 16:52:31

Base Information

Drug NameEfmoroctocog alfa
Drug Alias NameFactor VIII-Fc艾莫凝血素-8αLong-lasting factor VIII fusion protein艾芙莫罗凝血素αEfmoroctocog alpha/Efraloctocog alpha +[18] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/06/06
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSobiBiogen IncBioverativ Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncSwedish Orphan Biovitrum Ab (Publ)
Inactive CompaniesBioverativ, A Sanofi CompanyBioverativ Therapeutics Inc
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD02
Related LinksDrugBankKEGG